Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40012804
Localisation
United States of America
Northern America
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
25/01/2024
Statut
Classification
1.5°C
Année cible
FY2030
Catalent commits to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from an FY2022 base year. Catalent also commits to reduce absolute scope 3 GHG emissions from fuel- and energy-related activites, and employee commuting 25% within the same timeframe. Catalent further commits that 70% of its suppliers by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by FY2028.
Statut
BA1.5 memberDate d'engagement
22/07/2021
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
US1488061029
LEI
549300HALRZ339MSTH85
Source : Science Based Targets initiative | Données publiques